Stay updated with breaking news from Advanced Markets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
“She owns the home in her name only, and has a pension and Social Security. He has a 401(k) and Social Security.”
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara®, in the United States of America.
Sandoz will get the exclusive rights to promote, sell, and distribute Trastuzumab and Bevacizumab, which are used in the treatment of various cancers, in Australia
Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.
Being clear about your goals and surrounding yourself with the right partners and like-minded peers is key